19th August 2020
Cambridge, UK – 19 August 2020: Nuformix plc (LSE:NFX) (“Nuformix” or “the Group”), a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines to provide enhanced benefit, announces results from the pre-clinical pilot study and evaluation of its NXP004 fibrosis programme in human idiopathic pulmonary fibrosis (IPF), against standard of care. Download News